Cardiovascular, renal and metabolic (CVRM) diseases – including obesity and associated comorbidities such as diabetes, chronic kidney disease, heart and liver diseases – are deeply interconnected and place a growing burden on individuals, healthcare systems and societies. They affect a substantial share of adults globally and cause millions of deaths annually:
Despite the availability of numerous treatment options, significant gaps remain in addressing the unmet needs of patients, as many therapies have not significantly altered disease trajectories. Advances in human genetics and disease biology have identified new therapeutic targets, and innovative modalities such as siRNAs, ASOs, cell therapies, and gene silencing which are opening doors to treatments for previously untreatable conditions.
Roche is uniquely positioned to address these challenges with its comprehensive pipeline of potential best- and first-in-class investigational medicines, Diagnostics and Digital Solutions aimed at improving outcomes, reducing societal burdens, and transforming care for patients with CVRM diseases throughout their journey. We are highly committed to contributing to areas of highest unmet need and societal burden through transformative science, expanding our footprint in cardiovascular and metabolic diseases.
References
[1] Noubiaq et al. 2025, [2] WHO 2025, [3] IDF/Diabetes Atlas, [4] WHO 2025
Alnylam – Partnership to co-develop and co-commercialise zilebesiran, a RNAi therapy with best-in-class potential for patients with hypertension at high cardiovascular risk.
Carmot - Acquisition to access Carmot’s portfolio and expertise in incretins to treat obesity, diabetes and potentially other diseases, both as a monotherapy and in combination with existing and future Roche pipeline programs.
Zealand Pharma - Exclusive collaboration to co-develop and co-commercialise petrelintide, a long-acting amylin analog, both as a monotherapy and in combination with existing and future Roche pipeline programs including our lead incretin asset CT-388.
89bio - Acquisition of 89bio, with its clinical stage asset for the treatment of moderate to severe MASH (Metabolic Dysfunction-Associated Steatohepatitis), leveraging Roche's commitment to patients with cardiovascular, renal, and metabolic (CVRM) diseases.
Connect with our partnering experts to start the conversation.